Covid-19 roundup: New preprint suggests Omicron sub-variant can evade Vir antibody; BioNTech-backed nonprofit undermined WHO equity efforts — report

Max Gelman

Senior Editor

Jason Mast

Editor

After Omicron began spreading across the world, it quickly became clear that Vir-GSK’s antibody sotrovimab would be the only FDA-approved Covid-19 monoclonal antibody treatment to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: New preprint suggests Omicron sub-variant can evade Vir antibody; BioNTech-backed nonprofit undermined WHO equity efforts — report

Max Gelman

Senior Editor

Jason Mast

Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Covid-19 roundup: New preprint sug­gests Omi­cron sub-vari­ant can evade Vir an­ti­body; BioN­Tech-backed non­prof­it un­der­mined WHO eq­ui­ty ef­forts — re­port

Senior Editor

Editor

Sign up to read this article for free.

Covid-19 roundup: New preprint suggests Omicron sub-variant can evade Vir antibody; BioNTech-backed nonprofit undermined WHO equity efforts — report